[
    [
        {
            "time": "2021-08-25",
            "original_text": "复星医药创新成果落地 复星医药上半年业绩增长强劲",
            "features": {
                "keywords": [
                    "创新成果",
                    "业绩增长",
                    "复星医药"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药创新成果落地 复星医药上半年业绩增长强劲",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-08-26",
            "original_text": "复星医药创新药步入收获期，董事长吴以芳：希望未来打造50亿美元级重磅产品",
            "features": {
                "keywords": [
                    "创新药",
                    "收获期",
                    "重磅产品"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药创新药步入收获期，董事长吴以芳：希望未来打造50亿美元级重磅产品",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-08-27",
            "original_text": "北向资金连续三日加仓累计净买入超百亿，大幅抄底白酒股",
            "features": {
                "keywords": [
                    "北向资金",
                    "加仓",
                    "白酒股"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "白酒"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "北向资金连续三日加仓累计净买入超百亿，大幅抄底白酒股",
                "Correlation": 2,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 1,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-08-28",
            "original_text": "产经报道｜复星医药吴以芳：仿制药下行压力将会持续加大，坚定创新进入无人区",
            "features": {
                "keywords": [
                    "仿制药",
                    "下行压力",
                    "创新"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "产经报道｜复星医药吴以芳：仿制药下行压力将会持续加大，坚定创新进入无人区",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-08-30",
            "original_text": "疫苗“添柴”集采“减收” 复星医药将加大创新品种占比",
            "features": {
                "keywords": [
                    "疫苗",
                    "集采",
                    "创新品种"
                ],
                "sentiment_score": 0.75,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "疫苗“添柴”集采“减收” 复星医药将加大创新品种占比",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-09-01",
            "original_text": "复星医药A股涨超5% H股涨逾7% 郭广昌：复必泰在正常推进",
            "features": {
                "keywords": [
                    "A股",
                    "H股",
                    "复必泰"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药A股涨超5% H股涨逾7% 郭广昌：复必泰在正常推进",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-09-02",
            "original_text": "港股异动｜复星医药(2196.HK)涨4.6% 上半年复必泰疫苗收入超5亿元",
            "features": {
                "keywords": [
                    "港股",
                    "复必泰",
                    "疫苗收入"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "港股异动｜复星医药(2196.HK)涨4.6% 上半年复必泰疫苗收入超5亿元",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-09-03",
            "original_text": "郭广昌：复必泰审批进展正常 除了疫苗复星医药还有很多好产品",
            "features": {
                "keywords": [
                    "郭广昌",
                    "复必泰",
                    "审批进展"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "郭广昌：复必泰审批进展正常 除了疫苗复星医药还有很多好产品",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-09-05",
            "original_text": "复星医药：mRNA疫苗国内审批进展正常，首个细胞治疗产品已上市",
            "features": {
                "keywords": [
                    "mRNA疫苗",
                    "审批进展",
                    "细胞治疗"
                ],
                "sentiment_score": 0.85,
                "policy_related": "true",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药：mRNA疫苗国内审批进展正常，首个细胞治疗产品已上市",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-09-07",
            "original_text": "复星医药拉升 郭广昌称新冠mRNA疫苗复必泰审批进展正常",
            "features": {
                "keywords": [
                    "复必泰",
                    "审批进展",
                    "拉升"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药拉升 郭广昌称新冠mRNA疫苗复必泰审批进展正常",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        }
    ]
]